MS treatment changed blood cells linked to inflammation

Credibility

Interest

Share:1 min read

Key Takeaway

After treatment that reduces B cells, inflammation-linked blood cells became more common in people with MS.

What They Found

Researchers found a group of immune cells that carried many signals linked to inflammation. These cells made up about 8% of blood cells studied in healthy people, but less than 1% in untreated people with MS. After treatment that reduces B cells, this cell group became about six times more common in the blood. The cells also showed changes in signals linked to inflammation. Tests suggested these cells might be able to enter the brain and spinal cord, but the study did not show that they did.

Who Should Care and Why

The study examined blood samples from people with MS and healthy people. Some samples came from people with MS before and after treatment that reduces B cells. The findings describe changes in immune cells during treatment. They may help explain treatment effects beyond the reduction of B cells. The study did not measure whether these cell changes affected MS symptoms.

Important Considerations

You should know that researchers analyzed 64 blood samples, not necessarily 64 people. They followed blood cell changes over time, but the abstract does not give a participant count. These results do not show that the treatment improved MS or that these cells entered the brain.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research Treatment Updates

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News